Pgi13 Medication Use and Healthcare Resource Utilization Trends Among Adult Ulcerative Colitis Patients in the United States: 2007-2017

Hunter, Theresa; Farrar, Mallory; Dong, Yan; Choong, Casey; Naegeli, April N.

doi:10.1016/j.jval.2019.04.784

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…a Data on direct healthcare costs were reported by four publications [ 31 , 50 , 58 , 69 ]. b Data on HCRU were reported by 10 publications [ 39 , 44 , 50 , 52 , 55 , 58 , 61 , 69 , 78 , 79 ]. ADA adalimumab, ED emergency department, GOL golimumab, HCRU healthcare resource utilization, IFX infliximab, UST ustekinumab, VDZ vedolizumab, UC ulcerative colitis, US United States …”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis

et al. 2023

View full text Add to dashboard Cite

Introduction The clinical benefits of advanced therapies (i.e., biologics and small-molecule drugs) in the treatment of moderate-to-severe ulcerative colitis (UC) have been demonstrated; however, there is less clarity regarding the economic and health-related quality of life (HRQoL) impact of these treatments. We conducted a systematic literature review to synthesize data on cost, healthcare resource utilization (HCRU), and HRQoL for patients who received approved advanced therapies for moderate-to-severe UC in the United States and Europe. Methods Databases including MEDLINE, Embase, the Database of Abstracts of Reviews of Effects (DARE), the National Health Service Economic Evaluation Database (NHS EED), and EconLit were searched systematically to identify observational studies published between January 1, 2010 and October 14, 2021 that assessed the impact of advanced therapies on cost, HCRU, and/or HRQoL in adults with moderate-to-severe UC. Supplementary gray literature searches of conference proceedings from the past 4 years (January 2018 to October 2021) were also performed. Results 47 publications of 40 unique cost/HCRU studies and 13 publications of nine unique HRQoL studies were included. Findings demonstrated that biologics have a positive impact on indirect costs (i.e., productivity, presenteeism, and absenteeism) and HRQoL. High costs of biologics were not always fully offset by reductions in cost and HCRU associated with disease management. For many patients, treatment switching and dose escalations were required, thus increasing drug costs, particularly when switching across treatment classes. Conclusion These findings highlight a high unmet need for therapies for moderate-to-severe UC that can reduce the healthcare burden and impact on society. Further research is warranted, as the reported evidence was limited by the small sample sizes of some treatment groups within a study. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02488-z.

show abstract